Tekla Life Sciences Stock Today
| HQL Stock | USD 12.99 0.06 0.46% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Tekla Life is selling for 12.99 as of the 20th of March 2025. This is a 0.46 percent down since the beginning of the trading day. The stock's lowest day price was 12.94. Tekla Life has about a 44 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Note, on November 3, 2022, Senator Thomas R Carper of US Senate acquired under $15k worth of Tekla Life Sciences's common stock.
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States. Tekla Life operates under Asset Management classification in the United States and is traded on New York Stock Exchange.. The company has 28.06 M outstanding shares of which 96.46 K shares are currently shorted by investors with about 0.38 days to cover. More on Tekla Life Sciences
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Tekla Stock Highlights
| Chairman | Oleg Pohotsky |
| Business Concentration | Financials, Capital Markets, Asset Management, Financial Services (View all Sectors) |
Tekla Life Sciences (HQL) is traded on New York Stock Exchange in USA. It is located in 1900 Market Street, Philadelphia, PA, United States, 19103 and employs 11 people. The company currently falls under 'Small-Cap' category with a total capitalization of 369.85 M. Tekla Life Sciences runs under Capital Markets sector within Financials industry. The entity has 28.06 M outstanding shares of which 96.46 K shares are currently shorted by investors with about 0.38 days to cover.
Tekla Life Sciences has about 292.4 K in cash with (12.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Check Tekla Life Probability Of Bankruptcy
Ownership AllocationTekla Life Sciences shows a total of 28.06 Million outstanding shares. 30% of Tekla Life Sciences outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that on November 3, 2022, Senator Thomas R Carper of US Senate acquired under $15k worth of Tekla Life Sciences's common stock.
Check Tekla Ownership Details
Tekla Life Sciences Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Tekla Life market risk premium is the additional return an investor will receive from holding Tekla Life long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0) | |||
| Jensen Alpha | (0) | |||
| Total Risk Alpha | 0.0772 | |||
| Treynor Ratio | (0.09) |
Tekla Stock Against Markets
Tekla Life Corporate Management
| Thomas Kent | Independent Trustee | Profile | |
| William Reardon | Independent Trustee | Profile | |
| Elizabeth Nabel | Independent Trustee | Profile | |
| Laura Woodward | Chief Compliance Officer, Treasurer, Secretary | Profile | |
| Peter Branner | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Tekla Life Sciences is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Life's value that differs from its market value or its book value, called intrinsic value, which is Tekla Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Life's market value can be influenced by many factors that don't directly affect Tekla Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.